Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
Pharmacodynamic Models: Additive and Proportional Drug Effect Model01:09

Pharmacodynamic Models: Additive and Proportional Drug Effect Model

Drug response models describe how pharmacological agents interact with biological systems to produce measurable effects. Baseline responses are inherent physiological activities without a drug significantly influencing the observed pharmacological outcomes. Depending on the drug response model employed, these baseline responses may combine with the drug's effect in either an additive or proportional manner.Additive Drug Response ModelIn the additive model, the drug effect is independent of the...
Dosage Regimens: Designs and Approaches01:28

Dosage Regimens: Designs and Approaches

Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches01:14

Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches

Drug disposition in the body is a complex process and can be studied using two major approaches: the model and the model-independent approaches.
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Guideline for the Measurement, Analysis and Reporting of Medication Adherence during the Run-in phase of clinical trials (MARMAR).

Trials·2026
Same author

Meropenem and piperacillin/tazobactam optimised dosing regimens for critically ill patients receiving renal replacement therapy.

Intensive care medicine·2025
Same author

The Influence of Patient Factors on the Population Pharmacokinetics of Colchicine: Implications for Safe and Effective Dosing.

Clinical pharmacokinetics·2025
Same author

Medication adherence during the run-in phase of clinical trials: A systematic review of methodological and reporting rigour.

British journal of clinical pharmacology·2025
Same author

A Pharmacometric Workflow for Resolving Model Instability in Model Use-Reuse Settings.

CPT: pharmacometrics & systems pharmacology·2025
Same author

Evaluation of an optimized intermittent vancomycin dosing regimen in infants.

The Journal of antimicrobial chemotherapy·2025
Same journal

Design, Synthesis and Characterization of Anti-CTLA4 Peptide Conjugated Gemcitabine Prodrug Nanoparticles for Targeted Lung Cancer Chemoimmunotherapy.

Pharmaceutical research·2026
Same journal

Leveraging Carnitine-functionalized Lipid Nanocarrier based Targeted Delivery of A1874 PROTAC for Glioblastoma.

Pharmaceutical research·2026
Same journal

Impact of Febrile State on Vancomycin Clearance in Pediatric Patients: Insights From Population Pharmacokinetic Modeling.

Pharmaceutical research·2026
Same journal

Sustained Intra-Articular Delivery of Triple Therapeutics Using a Phase-Transition Phospholipid-Based Gel for Effective Treatment of Gouty Arthritis.

Pharmaceutical research·2026
Same journal

Spray Dried Lysozyme Microspheres: Morphological Evolution and Enzymatic Activity Retention.

Pharmaceutical research·2026
Same journal

Colloidal Stability of Amorphous Nanoparticles in Solution: Impact of Stabilizer.

Pharmaceutical research·2026
See all related articles

Related Experiment Video

Updated: Jun 4, 2026

Inverse Probability of Treatment Weighting (Propensity Score) using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting (Propensity Score) using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

Development of a bayesian forecasting method for warfarin dose individualization.

Daniel F B Wright1, Stephen B Duffull

  • 1School of Pharmacy, University of Otago, PO Box 56, Dunedin 9054, New Zealand. dan.wright@otago.ac.nz

Pharmaceutical Research
|February 9, 2011
PubMed
Summary
This summary is machine-generated.

A new Bayesian tool for warfarin dose individualization is now available in TCIWorks software. This tool uses pharmacokinetic and pharmacodynamic models to optimize warfarin dosing for patients.

More Related Videos

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

Related Experiment Videos

Last Updated: Jun 4, 2026

Inverse Probability of Treatment Weighting (Propensity Score) using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting (Propensity Score) using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

Area of Science:

  • Pharmacology
  • Pharmacometrics
  • Clinical Pharmacy

Background:

  • Warfarin dosing requires individualization due to its narrow therapeutic index.
  • Accurate pharmacokinetic and pharmacodynamic (PKPD) modeling is crucial for effective warfarin therapy.
  • Existing tools may lack robust Bayesian dose individualization capabilities.

Purpose of the Study:

  • To develop a Bayesian dose individualization tool for warfarin.
  • To integrate this tool into the TCIWorks software for clinical application.
  • To enhance warfarin management through personalized dosing strategies.

Main Methods:

  • Systematic literature review and evaluation of all published warfarin PKPD models.
  • Selection of the best-performing model based on external validation with two warfarin datasets.
  • Development of an optimal design for Bayesian parameter control using simulation-estimation techniques.
  • Implementation of the validated model and Bayesian design within the TCIWorks software.

Main Results:

  • A recently published warfarin PKPD model demonstrated the best fit for external datasets.
  • Optimal sampling days for Bayesian parameter estimation were identified as days 3, 4, 5, 11, 12, 13, and 14.
  • Simulation-estimation confirmed the design's ability to provide stable estimates of warfarin clearance and EC50.
  • A patient case demonstrated the clinical utility of the TCIWorks-integrated tool.

Conclusions:

  • A functional Bayesian dose individualization tool for warfarin has been successfully developed and integrated into TCIWorks.
  • Further research is warranted to prospectively evaluate the predictive performance of this tool in clinical warfarin management.
  • The tool has the potential to improve warfarin dosing precision and patient outcomes.